Publications by authors named "Edward Meier"

Claim this Profile
R
Rational design of antibodies with pH-dependent antigen-binding properties using structural insights from broadly neutralizing antibodies against α-neurotoxins.
Jack Wade, Nina Štrancar, Monica L Fernández-Quintero, Suzana Siebenhaar, Tom Jansen, Edward P W Meier

MAbs· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in antibody-based strategies for targeting cancer-associated glycopeptide antigens.
Edward P W Meier, Andreas H Laustsen

Drug Discov Today· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Punctal Occlusion on Ocular Itching and Conjunctival Redness Associated with Allergic Conjunctivitis.
Steven M Silverstein, Michelle A Sato, Edward J Meier, Stella Dai, Aditi Bauskar

Curr Eye Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Rapid and reversible alteration in corneal contour and power associated with Netarsudil/Latanoprost".
David Chung, Edward J Meier

Am J Ophthalmol Case Rep· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular analysis of an enigmatic virulence factor: The raffinose-family oligosaccharide utilization system.
Joanne K Hobbs, Edward P W Meier, Benjamin Pluvinage, Mackenzie A Mey, Alisdair B Boraston

J Biol Chem· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects.
Ranjan P Malhotra, Edward Meier, Gail Torkildsen, Paul J Gomes, Mark C Jasek

Clin Ophthalmol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model.
Edward J Meier, Gail L Torkildsen, Paul J Gomes, Mark C Jasek

Clin Ophthalmol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies.
Edward Meier, Abhijit Narvekar, Ganesh R Iyer, Harvey B DuBiner, Apinya Vutikullird

Clin Ophthalmol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.
Edward J Meier, Gail L Torkildsen, James A Gow, Timothy R McNamara, Paul J Gomes

Allergy Asthma Proc· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
Gail L Torkildsen, Paul Cockrum, Edward Meier, William M Hammonds, Bruce Silverstein

Curr Med Res Opin· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis